Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.

Abstract

The efficacy of second-line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second-line therapy have been rare. We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan-based chemotherapy could be a good option for second-line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.

• Authors: Guk Jin Lee, Ji Won Min, Min Wu Seo, Mi Yeong Lee, Jong Youl Jin
• Journal: The journal of obstetrics and gynaecology research (J Obstet Gynaecol Res) Vol. 40 Issue 1 Pg. 297-300 (Jan 2014) ISSN: 1447-0756 [Electronic] Australia
• PMID: 24102892 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.

Chemical References

• Antineoplastic Agents
• Topoisomerase I Inhibitors
• belotecan
• Cisplatin
• Camptothecin

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Camptothecin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Carcinoma (drug therapy)
• Cisplatin (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Neoplasm Recurrence, Local (drug therapy)
• Peritoneal Neoplasms (drug therapy)
• Peritoneum (drug effects)
• Topoisomerase I Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome